CAJ | 학술논문

目的观察血管紧张素受体拮抗剂(immunoglobulin A nephropathy,ARB)在不同病理类型IgAN患者中的疗效及安全性.方法根据Lee氏分级,将30例患者分为Lee氏2级组(3例、)Lee氏3级组(18例)和Lee氏4级组(9例),都服用相同剂量的ARB(替米沙坦80mg/d),并进行了长达1年的随访,观察收缩压、舒张压、血肌酐、尿素氮、尿酸、eGFR、血糖、胆固醇、甘油三酯、血钾、高倍镜下红细胞及24h尿蛋白等变化情况.结果替米沙坦治疗1年后,Lee氏2级组患者的尿蛋白缓解率为100％,Lee氏3级组为43.8％,而Lee氏4级组仅为11.1％.与入组时基线值相比,各组各时间点血肌酐、尿素氮、尿酸、eGFR、血糖、胆固醇、甘油三酯及血钾均没有明显变化.结论 IgAN患者ARB的使用是相对安全、有效的,但其病理类型直接影响ARB药物的治疗效果.
목적 관찰혈관긴장소수체길항제(immunoglobulin A nephropathy,ARB)재불동병리류형IgAN환자중적료효급안전성.방법 근거Lee씨분급,장30례환자분위Lee씨2급조(3례、)Lee씨3급조(18례)화Lee씨4급조(9례),도복용상동제량적ARB(체미사탄80mg/d),병진행료장체1년적수방,관찰수축압、서장압、혈기항、뇨소담、뇨산、eGFR、혈당、담고순、감유삼지、혈갑、고배경하홍세포급24h뇨단백등변화정황.결과 체미사탄치료1년후,Lee씨2급조환자적뇨단백완해솔위100％,Lee씨3급조위43.8％,이Lee씨4급조부위11.1％.여입조시기선치상비,각조각시간점혈기항、뇨소담、뇨산、eGFR、혈당、담고순、감유삼지급혈갑균몰유명현변화.결론 IgAN환자ARB적사용시상대안전、유효적,단기병리류형직접영향ARB약물적치료효과.
Objectives To observe the efficacy and safety of ARB in IgAN patients with different pathological types.Methods According to Lee's classification,the patients were divided into three groups:Lee's 2 group,Lee's 3 group and Lee's 4 group.All patients take the same dose ARB (telmisartan 80 mg / d),and we follow-up observed the patients'systolic blood pressure,diastolic blood pressure,serum creatinine,blood urea nitrogen,uric acid,eGFR,blood sugar,cholesterol,triglycerides,blood potassium,high magnification RBC and 24h urine protein changes for at least one year.Results After treated with Telmisartan for one year,the urine protein response rate in the 3 groups were 100％,43.8％ and 11.1％ respectively.And compared to baseline values,the serum creatinine,blood urea nitrogen,uric acid,eGFR,blood sugar,cholesterol,triglycerides and blood potassium did not change significantly.Conclusions ARB is relatively safe and effective in IgAN patients but the pathological type a direct impact on the therapeutic effect of ARB drugs.